Acutus Medical (AFIB) Stock Price

Acutus Medical Price

NASDAQ·CLOSED
0.00USD+0.00 (+0.00 %)
Market closed

Revenue has compounded at 45.0% per year over the past 6 years to 20.16 M USD. Acutus Medical's net margin stands at -47.4%, up from -1,204.9% several years earlier. Analysts set a median price target of 1.53 USD, implying 1,529,900.0% above the current price. Of 9 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 527,900% above its 52-week low.

Acutus Medical stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Acutus Medical over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Acutus Medical stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Acutus Medical's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Acutus Medical Stock Price History
DateAcutus Medical Price
8/6/20260.00 USD
8/5/20260.00 USD
8/4/20260.00 USD
8/3/20260.00 USD
7/30/20260.00 USD
7/29/20260.00 USD
7/28/20260.00 USD
7/27/20260.00 USD
7/24/20260.00 USD
7/23/20260.00 USD
7/22/20260.00 USD
7/21/20260.00 USD
7/20/20260.00 USD
7/17/20260.00 USD
7/16/20260.00 USD
7/15/20260.00 USD
7/14/20260.00 USD
7/13/20260.00 USD
7/10/20260.00 USD
7/9/20260.00 USD
7/8/20260.00 USD
7/7/20260.00 USD
7/6/20260.00 USD
7/2/20260.00 USD
7/1/20260.00 USD
6/30/20260.00 USD
6/29/20260.00 USD
6/26/20260.00 USD
6/25/20260.00 USD
6/24/20260.00 USD
6/23/20260.00 USD
6/22/20260.00 USD
6/18/20260.00 USD
6/17/20260.00 USD
6/16/20260.00 USD
6/15/20260.00 USD
6/12/20260.00 USD
6/11/20260.00 USD
6/10/20260.00 USD
6/9/20260.00 USD
6/8/20260.00 USD
6/5/20260.00 USD
6/4/20260.00 USD
6/3/20260.00 USD
6/2/20260.00 USD
6/1/20260.00 USD
5/29/20260.00 USD
5/28/20260.00 USD
5/27/20260.00 USD
5/26/20260.00 USD
5/22/20260.00 USD
5/21/20260.00 USD
5/20/20260.00 USD
5/19/20260.00 USD
5/18/20260.00 USD
5/12/20260.00 USD
5/11/20260.00 USD
5/8/20260.00 USD
5/7/20260.00 USD
5/6/20260.00 USD
5/5/20260.00 USD
5/4/20260.00 USD
5/1/20260.00 USD
4/21/20260.00 USD
4/20/20260.00 USD
4/17/20260.00 USD
4/15/20260.00 USD
4/13/20260.00 USD
4/10/20260.00 USD
4/9/20260.00 USD
4/8/20260.00 USD
4/2/20260.00 USD
4/1/20260.00 USD
3/18/20260.00 USD
3/9/20260.00 USD
3/5/20260.00 USD
3/2/20260.00 USD
2/27/20260.00 USD
2/25/20260.00 USD
2/24/20260.00 USD
2/20/20260.00 USD
2/19/20260.00 USD
2/17/20260.00 USD
2/12/20260.00 USD
2/11/20260.00 USD
2/10/20260.00 USD
2/6/20260.00 USD
2/5/20260.00 USD
2/4/20260.00 USD
1/26/20260.00 USD
1/23/20260.00 USD
1/22/20260.00 USD
1/21/20260.00 USD
1/20/20260.00 USD
1/14/20260.00 USD
1/13/20260.00 USD
1/12/20260.00 USD
1/9/20260.00 USD
1/7/20260.00 USD
1/5/20260.00 USD
1/2/20260.00 USD
12/31/20250.00 USD
12/30/20250.00 USD
12/29/20250.00 USD
12/26/20250.00 USD
12/24/20250.00 USD
12/23/20250.00 USD
12/22/20250.00 USD
12/19/20250.00 USD
12/18/20250.00 USD
12/16/20250.00 USD
12/15/20250.00 USD
12/12/20250.00 USD
12/11/20250.00 USD
12/10/20250.00 USD
12/9/20250.00 USD
12/8/20250.00 USD
12/5/20250.00 USD
11/28/20250.00 USD
11/25/20250.00 USD
11/24/20250.00 USD
11/21/20250.00 USD
11/20/20250.00 USD
11/19/20250.00 USD
11/14/20250.00 USD
11/13/20250.00 USD
11/12/20250.00 USD
11/11/20250.00 USD
11/10/20250.00 USD
11/7/20250.00 USD
11/5/20250.00 USD
11/4/20250.00 USD
11/3/20250.00 USD
10/31/20250.00 USD
10/30/20250.00 USD
10/29/20250.00 USD
10/28/20250.00 USD
10/27/20250.00 USD
10/24/20250.00 USD
10/23/20250.00 USD
10/22/20250.00 USD
10/21/20250.00 USD
10/20/20250.00 USD
10/17/20250.00 USD
10/16/20250.00 USD
10/15/20250.00 USD
10/14/20250.00 USD
10/13/20250.00 USD
10/10/20250.00 USD
10/9/20250.00 USD
10/8/20250.00 USD
10/6/20250.00 USD
10/3/20250.00 USD
10/2/20250.00 USD
10/1/20250.00 USD
9/30/20250.00 USD
9/19/20250.00 USD
9/18/20250.00 USD
9/16/20250.00 USD
9/12/20250.00 USD
9/11/20250.00 USD
9/9/20250.00 USD
9/5/20250.00 USD
9/4/20250.00 USD
9/3/20250.00 USD
9/2/20250.00 USD
8/29/20250.00 USD
8/28/20250.00 USD
8/27/20250.00 USD
8/26/20250.00 USD
8/25/20250.00 USD
8/22/20250.00 USD
8/20/20250.00 USD
8/19/20250.00 USD
8/18/20250.00 USD
8/15/20250.00 USD
8/14/20250.00 USD
8/12/20250.00 USD
8/11/20250.00 USD
Access this data via the Eulerpool API
Get Free API Key

Acutus Medical Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
17.26 M USD
-112.12 M USD
-117.68 M USD
Jan 1, 2022
3.03 M USD
34.00 M USD
-39.62 M USD
Jan 1, 2023
7.16 M USD
-14.36 M USD
-81.66 M USD
Jan 1, 2024
20.16 M USD
-57,000.00 USD
-9.55 M USD
Jan 1, 2025 (e)
56.50 M USD
-20.40 M USD
-56.26 M USD
Jan 1, 2026 (e)
98.80 M USD
-35.67 M USD
-40.19 M USD
Jan 1, 2027 (e)
162.50 M USD
-58.67 M USD
-17.86 M USD
Jan 1, 2028 (e)
180.23 M USD
0.00 USD
0.00 USD

Acutus Medical Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 9, 2026, 8:18 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20182019202020212022202320242025e2026e2027e2028e
2.002.008.0017.003.007.0020.0056.0098.00162.00180.00
––300.00112.50-82.35133.33185.71180.0075.0065.3111.11
-250.00-300.00-87.50-88.24-33.33-42.865.005.005.005.005.00
-5.00-6.00-7.00-15.00-1.00-3.001.002.804.908.109.00
-42.00-75.00-91.00-112.0033.00-14.00–-20.00-35.00-58.00–
-2,100.00-3,750.00-1,137.50-658.821,100.00-200.00–-35.71-35.71-35.80–
-47.00-97.00-101.00-117.00-39.00-81.00-9.00-56.00-40.00-17.00–
–106.384.1215.84-66.67107.69-88.89522.22-28.57-57.50–
1.0017.2727.9027.9537.2429.3129.7729.7729.7729.7729.77
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Acutus Medical generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Acutus Medical retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Acutus Medical's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Acutus Medical has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Acutus Medical's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Acutus Medical stock margins

The Acutus Medical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Acutus Medical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Acutus Medical.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
-87.72 %
-1,079.08 %
-1,204.88 %
Jan 1, 2021
-90.73 %
-649.49 %
-681.71 %
Jan 1, 2022
-63.02 %
1,121.64 %
-1,307.03 %
Jan 1, 2023
-43.79 %
-200.46 %
-1,139.91 %
Jan 1, 2024
5.03 %
-0.28 %
-47.36 %
Jan 1, 2025 (e)
5.03 %
-36.10 %
-99.58 %
Jan 1, 2026 (e)
5.03 %
-36.10 %
-40.68 %
Jan 1, 2027 (e)
5.03 %
-36.10 %
-10.99 %

Acutus Medical Stock Revenue, EBIT, Earnings per Share

The Acutus Medical earnings per share therefore indicates how much revenue Acutus Medical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.30 USD
-3.27 USD
-3.66 USD
Jan 1, 2021
0.62 USD
-4.01 USD
-4.21 USD
Jan 1, 2022
0.08 USD
0.91 USD
-1.06 USD
Jan 1, 2023
0.24 USD
-0.49 USD
-2.79 USD
Jan 1, 2024
0.68 USD
-0.00 USD
-0.32 USD
Jan 1, 2025 (e)
1.90 USD
-0.69 USD
-1.89 USD
Jan 1, 2026 (e)
3.32 USD
-1.20 USD
-1.35 USD
Jan 1, 2027 (e)
5.46 USD
-1.97 USD
-0.60 USD

Acutus Medical business model & stock analysis

The company Acutus Medical Inc was founded in 2011 and is headquartered in California, USA. The company aims to develop innovative technologies to improve the procedures in the diagnosis and treatment of heart disease. The company employs over 300 employees worldwide and has various locations in the USA and Europe. Acutus Medical Inc's business model is based on the development and marketing of products to improve the diagnosis and treatment options for heart disease. This includes both electrophysiological products for assessing heartbeats and treatment products for regulating heart rate. An important division of the company is electrophysiological diagnostics. Products are produced here that measure and record the electrical impulse of the heart. This is done, for example, through catheters that are inserted into the heart and use electromagnetic technologies to create an accurate mapping of the heart's electrical activity. This information can help doctors better understand the condition and function of the heart and make informed decisions regarding treatment. Another important area of Acutus Medical Inc is the therapy of heart disease. The company offers innovative treatment products that help regulate heart rhythm and treat cardiac arrhythmias. Particularly noteworthy here is the product "AcQMap," which enables the use of electromagnetic technologies for mapping the heart and identifying heart rhythm disorders. This allows doctors to develop more targeted treatment strategies and improve treatment accuracy. Another important division of Acutus Medical Inc is the research and development of new technologies to improve the diagnosis and therapy of heart disease. The company works closely with doctors and research institutes to drive product and procedure innovation. Overall, Acutus Medical Inc is an innovative company specializing in the development of technologies to improve the diagnosis and treatment of heart disease. The company operates internationally and offers a wide range of innovative products for electrophysiological diagnostics and therapy of heart disease. Through close collaboration with doctors and research institutes, Acutus Medical succeeds in improving existing procedures and developing new approaches for the treatment of heart disease.

Acutus Medical SWOT Analysis

Strengths

Acutus Medical Inc possesses several strengths that contribute to its competitive advantage and position in the market. These strengths include:

  • Advanced Technology: Acutus Medical Inc is known for its cutting-edge medical technology and innovative products.
  • Strong Intellectual Property: The company holds a solid portfolio of patents and intellectual property rights, providing a barrier to entry for competitors.
  • Skilled Team: Acutus Medical Inc is backed by a highly skilled team of experts in the field of medical technology, allowing for efficient development and improvement of their products.
  • Strong Financial Position: The company has a strong financial standing, allowing for investments in research and development, marketing, and expansion.
  • Strategic Partnerships: Acutus Medical Inc has established strategic partnerships with key industry players, enhancing its market reach and distribution networks.

Weaknesses

Despite its strengths, Acutus Medical Inc also faces certain weaknesses that may hinder its growth and performance:

  • Limited Market Presence: The company's presence in certain geographic regions or market segments may be relatively weak, limiting its market share.
  • High Research and Development Costs: Developing and improving advanced medical technology involves significant investments in research and development, which may strain the company's financial resources.
  • Dependency on Key Employees: Acutus Medical Inc may be highly dependent on key individuals to drive innovation, and the loss of such talent could impact its operations.

Opportunities

Several opportunities exist for Acutus Medical Inc to further expand and succeed in the market:

  • Market Growth Potential: The global medical technology market continues to experience substantial growth, providing opportunities for Acutus Medical Inc to expand its customer base and market share.
  • Product Diversification: Acutus Medical Inc can explore diversifying its product portfolio by expanding into different medical fields or developing complementary offerings.
  • Emerging Markets: Targeting emerging markets presents an opportunity for the company to tap into new customer segments and gain a competitive advantage.
  • Innovation and Improvements: Investing in continuous innovation and product improvements can enhance Acutus Medical Inc's market position and differentiation.

Threats

Acutus Medical Inc faces certain threats that could impact its business and market performance:

  • Intense Competition: The medical technology industry is highly competitive, with numerous established players and new entrants. This competition may impact pricing and market share.
  • Regulatory Challenges: Compliance with strict regulations and obtaining necessary approvals for medical devices can be time-consuming and cost-intensive.
  • Economic Uncertainty: Economic downturns or fluctuations in healthcare spending can affect the demand and adoption of Acutus Medical Inc's products.
  • Technological Advancements: Rapid advancements in technology may lead to the emergence of alternative or more advanced medical solutions, posing a threat to Acutus Medical Inc's market position.

Acutus Medical Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Acutus Medical Employees
Details
Date
Acutus Medical Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees

Acutus Medical Segments

Acutus Medical Revenue by Segment (1/3)

  • Max

Systems
Details
Date
Disposables
Service/Other
Systems
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD

Acutus Medical Revenue by Segment (2/3)

  • Max

Disposables
Service/Other
Details
Date
Disposables
Service/Other
Jan 1, 2024
0.00 USD
0.00 USD

Acutus Medical Revenue by Segment (3/3)

  • Max

Reportable Segment
Details
Date
Reportable Segment
Jan 1, 2024
20.16 M USD

Acutus Medical Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Acutus Medical historical P/E ratio, EBIT multiple, and P/S ratio

Acutus Medical annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Acutus Medical shares outstanding

The number of shares of Acutus Medical was 29.77 M in 2025. This indicates how many shares Acutus Medical is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
27.90 M Stocks
Jan 1, 2021
27.95 M Stocks
Jan 1, 2022
37.24 M Stocks
Jan 1, 2023
29.31 M Stocks
Jan 1, 2024
29.77 M Stocks
Jan 1, 2025 (e)
29.77 M Stocks
Jan 1, 2026 (e)
29.77 M Stocks
Jan 1, 2027 (e)
29.77 M Stocks

Current Acutus Medical forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
66.67 % (6)
Hold
33.33 % (3)
Sell
0.00 % (0)
12M Price Target
1.53
Last Price
0.00
Currency
USD
12M Return Potential
1,529,900.04 %
LTM Return
0 %

Acutus Medical Analyst Rating Actions

DateFirmActionRatingReliability
8/16/2022
Goldman Sachs
Goldman Sachs
MaintainedNeutral–
6/24/2022
BTIG
BTIG
MaintainedBuy–
4/27/2022
BTIG
BTIG
UpgradeNeutralBuy–
4/14/2022
Goldman Sachs
Goldman Sachs
MaintainedNeutral–
1/20/2022
BTIG
BTIG
DowngradeBuyNeutral–
1/14/2022
Canaccord Genuity
Canaccord Genuity
DowngradeBuyHold59
11/12/2021
JP Morgan
JP Morgan
DowngradeNeutralUnderweight80
11/12/2021
Canaccord Genuity
Canaccord Genuity
MaintainedBuy59
7/15/2021
Canaccord Genuity
Canaccord Genuity
UpgradeHoldBuy59
3/19/2021
William Blair
William Blair
DowngradeOutperformMarket Perform–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Acutus Medical Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
11/6/2024-0.44USD-8.42 MUSD-2024 Q3
5/9/2024-0.50USD-6.60 MUSD-2024 Q1
3/14/2024-0.54USD-6.64 MUSD-2023 Q4
11/8/2023-0.62USD-5.37 MUSD-2023 Q3
8/9/2023-0.65USD-5.11 MUSD-2023 Q2
5/10/2023-0.68USD-4.76 MUSD-2023 Q1
3/28/2023-0.76USD-4.51 MUSD-2022 Q4
11/10/2022-0.82USD-3.70 MUSD-2022 Q3
8/11/2022-0.81USD-3.89 MUSD-2022 Q2
5/12/2022-0.94USD-3.17 MUSD-2022 Q1

EESG©

Eulerpool ESG Scorecard© for the Acutus Medical stock

16/100
5
Environment
21
Social
23
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Acutus Medical shareholder structure

% Name
0.00000%
Guggenheim Investments
Guggenheim Investments
0.00000%
S.A. Mason LLC
S.A. Mason LLC

Acutus Medical Beneficial Ownership Filings (SEC 13D/G)

Free Float
67.3%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
20.90%
OrbiMed Advisors LLC
OrbiMed Advisors LLC
SEC ↗
15.30%
OrbiMed Capital GP IV LLC
OrbiMed Capital GP IV LLC
SEC ↗
11.00%
Laurence W. Lytton
Laurence W. Lytton
SEC ↗
9.10%
James E. Flynn
James E. Flynn
SEC ↗
5.80%
Shahzad Malik
Shahzad Malik
SEC ↗
5.80%
Advent Life Sciences Fund I LP
Advent Life Sciences Fund I LP
SEC ↗
5.80%
OrbiMed ROF II LLC
OrbiMed ROF II LLC
SEC ↗
5.70%
95-1411037
95-1411037
SEC ↗
5.42%
Deerfield Private Design Fund III, L.P.
Deerfield Private Design Fund III, L.P.
SEC ↗
5.42%
Deerfield Mgmt III, L.P.
Deerfield Mgmt III, L.P.
SEC ↗

Acutus Medical Executives and Management Board

6 members · avg. age 54 · 33 % women

SM

Dr. Shaden Marzouk (54)

Independent Chairperson of the Board

73,750.00 USD
JG

Mr. Jason Garland (51)

Independent Director

60,000.00 USD
NP

Ms. Niamh Pellegrini (58)

Independent Director

57,000.00 USD
JS

Mr. John Sheridan (69)

Independent Director

56,500.00 USD
AE

Dr. Andrew Elbardissi (43)

Independent Director

52,000.00 USD
DB

Dr. David Bonita (49)

Independent Director

50,000.00 USD

Acutus Medical Supply Chain

Frequently asked questions about Acutus Medical

The business model of Acutus Medical Inc. revolves around medical technologies and solutions for cardiac arrhythmia treatment. Acutus Medical specializes in developing and commercializing innovative electrophysiology platforms and mapping systems that provide real-time, high-resolution mapping of the heart. With a focus on improving the accuracy and efficiency of procedures, Acutus Medical's products enable physicians to better diagnose and treat arrhythmias. The company's advanced technology aims to enhance patient outcomes and streamline healthcare delivery. Acutus Medical Inc. is committed to advancing the field of electrophysiology through continuous innovation and collaboration with healthcare professionals.

Acutus Medical Inc is primarily active in the healthcare industry, specifically focusing on medical devices and technologies for the treatment of cardiac arrhythmias. With their innovative solutions and advanced visualization technologies, Acutus Medical aims to improve the diagnosis and treatment of cardiac arrhythmias, providing physicians with real-time, precise, and detailed information to guide their procedures. By combining electrophysiology and imaging, Acutus Medical revolutionizes how cardiac arrhythmias are managed, offering potential benefits for patients and healthcare professionals in the field of cardiac care.

The main competitors of Acutus Medical Inc in the market include companies such as Biosense Webster, Abbott Laboratories, and Boston Scientific Corporation.

Acutus Medical Inc. is a medical technology company specializing in providing cardiac mapping and ablation systems for the treatment of complex arrhythmias. Founded in 2011, the company has quickly gained recognition for its innovative solutions in electrophysiology. Acutus Medical Inc. is committed to improving patients' lives by providing advanced technologies that enable physicians to diagnose and treat cardiac conditions more accurately and effectively. With a team of experienced professionals and a commitment to research and development, Acutus Medical Inc. continues to be at the forefront of advancing medical technology in the field of electrophysiology. From its inception, the company has focused on revolutionizing the way cardiac arrhythmias are diagnosed and treated, making them a trusted name in the healthcare industry.

Acutus Medical Inc has achieved several significant milestones in its history. One notable accomplishment was the development and introduction of the AcQMap imaging and mapping system, which revolutionized cardiac electrophysiology procedures by providing highly detailed 3D mapping of the heart. The company also made strides in expanding its global presence through strategic partnerships and key regulatory approvals. Moreover, Acutus Medical Inc successfully completed its initial public offering (IPO) in 2019, further strengthening its financial position and enabling continued innovation in the field of electrophysiology. These achievements have solidified Acutus Medical Inc's reputation as a leading player in the cardiac mapping and ablation market.

Acutus Medical Inc is primarily present in various countries and regions around the world. The company has a global presence, with a focus on key markets such as the United States, Europe, and Asia. Acutus Medical Inc has established a strong presence in the United States, where it is headquartered and operates its main operations. Additionally, the company has expanded its footprint in Europe, targeting countries like Germany, France, and the United Kingdom. Acutus Medical Inc is also actively present in the Asia-Pacific region, with a particular focus on markets in Japan, China, and Australia.

Acutus Medical Inc represents a strong commitment to innovation, cutting-edge technology, and delivering optimal patient care. The company's corporate philosophy focuses on developing advanced solutions for cardiac arrhythmia treatment, empowering healthcare professionals, and improving patient outcomes. Acutus Medical is dedicated to transforming the field of electrophysiology by providing precise and accurate mapping and ablation solutions, enabling customized therapy options. With a patient-centric approach, Acutus Medical strives to revolutionize the treatment of complex arrhythmias and enhance the quality of life for individuals with cardiac conditions. By continually pushing boundaries and embracing a culture of excellence, Acutus Medical is at the forefront of revolutionizing electrophysiology interventions.

Analysts currently set an average price target of 1.53 USD for the Acutus Medical stock (median: 1.53 USD), implying +1.5 M % versus the latest price. The consensus is based on 9 analyst ratings.

Acutus Medical Analyst Price Targets 2026

6 analysts currently rate the Acutus Medical stock: 0 recommend buying, 3 holding and 3 selling. For 2026, analysts expect Acutus Medical to generate revenue of 98.80 M USD and earnings per share of -1.35 USD.

Acutus Medical Analyst Price Targets 2026

Converted at the current exchange rate, the Acutus Medical share trades at 0.00 EUR (0.00 USD).

The Acutus Medical share (AFIB) is listed on 1 stock exchanges, including: NASDAQ (AFIB).

Acutus Medical Inc is a leading company in the field of electrophysiological imaging in medicine. Through the use of state-of-the-art technology and advanced imaging solutions, the company offers a wide range of products and services for the treatment of cardiac arrhythmias.

The expected revenue of Acutus Medical is 98.80 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Acutus Medical is -40.19 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Acutus Medical is currently -0.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Acutus Medical stock.

The price-to-sales ratio (P/S) of Acutus Medical is currently 0.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Acutus Medical stock.

The Eulerpool Quality Score for Acutus Medical is 2/10.

The ISIN of Acutus Medical is US0051111096. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Acutus Medical is AFIB. The ticker symbol is used to trade Acutus Medical shares on the stock exchange.

Acutus Medical paid dividends every year for the past 0 years.

Acutus Medical is assigned to the 'Health' sector.

The dividends of Acutus Medical are distributed in USD.

All fundamentals and in-depth analysis of Acutus Medical

Our stock analysis for Acutus Medical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Acutus Medical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Acutus Medical Stock
Acutus Medical Revenue→
Acutus Medical Stock
Acutus Medical Net Income→
Acutus Medical Stock
Acutus Medical P/E→
Acutus Medical Stock
Acutus Medical P/S→
Acutus Medical Stock
Acutus Medical EBIT→
Acutus Medical Stock
Acutus Medical Dividend→
Acutus Medical Stock
Acutus Medical Directors Dealings→
Acutus Medical Stock
Acutus Medical Stocks→
Acutus Medical Stock
Acutus Medical Market capitalization→
Acutus Medical Stock
Acutus Medical Debt→
Acutus Medical Stock
Acutus Medical Liabilities→
Acutus Medical Stock
Acutus Medical Equity→
Acutus Medical Stock
Acutus Medical AAQS→
Acutus Medical Stock
Acutus Medical Employees→
Acutus Medical Stock
Acutus Medical ROE→
Acutus Medical Stock
Acutus Medical ROA→
Acutus Medical Stock
Acutus Medical ROCE→
Acutus Medical Stock
Acutus Medical News→
Acutus Medical Stock
Acutus Medical Analyst Price Targets→

Health Stocks

AdageneAcutaas ChemicalsAdaltaAcusphereAdapthealthAcurx PharmaceuticalsAdaptive BiotechnologiesAcura PharmaceuticalsADBiotech CoAcumen PharmaceuticalsADC TherapeuticsAcuCortAll Stocks A–Z →